Alivus Life Sciences Ltd

Alivus Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alivus Life Sciences Ltd

₹ 1,046 2.80%
12 Jun - close price
glenmarklifesciences.com BSE: 543322 NSE: ALIVUS
About

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Key Points

History
Before 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated from GPL into GLS through a Business Transfer Agreement in Jan 2019, and GLS was subsequently listed on NSE & BSE in FY22. [1]

Website BSE NSE
  • Market Cap ₹ 12,835 Cr.
  • Current Price ₹ 1,046
  • High / Low ₹ 1,149 / 819
  • Stock P/E 22.0
  • Book Value ₹ 271
  • Dividend Yield 0.48 %
  • ROCE 25.0 %
  • ROE 19.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 27.4%

Cons

  • The company has delivered a poor sales growth of 6.24% over past five years.
  • Company has high debtors of 153 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
621 578 595 573 537 589 507 642 650 602 588 673 689
415 385 428 400 395 429 373 452 451 430 409 442 475
Operating Profit 206 193 167 173 141 159 134 190 198 172 179 231 215
OPM % 33% 33% 28% 30% 26% 27% 27% 30% 31% 29% 30% 34% 31%
3 2 5 2 3 5 9 10 10 9 15 -12 23
Interest 0 0 0 0 0 0 0 0 1 1 1 1 1
Depreciation 12 13 13 13 15 14 15 15 16 17 18 20 20
Profit before tax 198 182 159 161 130 150 127 185 191 163 174 198 216
Tax % 26% 26% 25% 26% 24% 26% 25% 26% 26% 25% 25% 24% 25%
146 135 119 119 98 111 95 137 142 122 130 150 163
EPS in Rs 11.95 11.05 9.69 9.69 7.99 9.10 7.78 11.18 11.58 9.91 10.60 12.25 13.25
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 886 1,537 1,885 2,123 2,161 2,283 2,387 2,552
0 638 1,064 1,294 1,506 1,518 1,608 1,702 1,755
Operating Profit -0 248 473 592 617 643 675 684 797
OPM % -4% 28% 31% 31% 29% 30% 30% 29% 31%
0 -0 11 0 14 28 11 33 35
Interest 0 1 34 88 28 1 2 2 5
Depreciation 0 19 29 33 38 42 53 61 75
Profit before tax -0 228 421 471 565 629 631 654 751
Tax % 4,200% 14% 26% 25% 26% 26% 25% 26% 25%
-0 196 313 352 419 467 471 486 564
EPS in Rs -430.00 997.86 1,597.37 358.74 34.17 38.11 38.43 39.63 45.99
Dividend Payout % 0% 0% 0% 0% 61% 110% 59% 13% 11%
Compounded Sales Growth
10 Years: %
5 Years: 6%
3 Years: 6%
TTM: 7%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: 8%
TTM: 21%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 20%
1 Year: 3%
Return on Equity
10 Years: %
5 Years: 21%
3 Years: 19%
Last Year: 19%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.01 2 2 2 25 25 25 25 25
Reserves -1 86 400 751 2,030 2,114 2,308 2,793 3,308
0 0 0 0 3 19 17 57 57
1 1,387 1,324 1,244 414 545 501 537 594
Total Liabilities 0 1,475 1,726 1,997 2,471 2,702 2,850 3,411 3,983
0 456 546 573 595 781 805 955 1,048
CWIP 0 80 11 14 92 62 106 102 273
Investments 0 0 0 0 0 0 0 478 780
0 939 1,169 1,410 1,784 1,860 1,939 1,877 1,881
Total Assets 0 1,475 1,726 1,997 2,471 2,702 2,850 3,411 3,983

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-0 10 195 388 598 306 414 392 565
0 -9 -51 -69 -122 -147 -116 -616 -570
0 1 -137 -214 -79 -388 -279 -6 -64
Net Cash Flow 0 2 8 106 397 -228 18 -230 -69
Free Cash Flow -0 1 144 322 466 143 285 226 259
CFO/OP 4,800% 14% 61% 84% 119% 71% 85% 81% 93%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 44 185 152 120 116 136 122 148 153
Inventory Days 162 441 227 214 185 224 251 237 237
Days Payable 41 201 111 92 110 158 139 137 127
Cash Conversion Cycle 165 424 268 241 190 202 235 248 263
Working Capital Days -2,059 -186 -37 12 149 176 188 201 306
ROCE % 529% 186% 97% 42% 30% 28% 25% 25%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Expenditure as percentage of Sales
%

Log in to view insights

Please log in to see hidden values.

Login
Cumulative DMF and CEP Filings
Count
Number of Unique Molecules in API Portfolio
Count
Fixed Assets Turnover Ratio
Times
Total Installed Reactor Capacity
KL
Capacity Utilization
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
82.85% 82.85% 82.85% 82.85% 82.85% 75.00% 75.00% 74.99% 74.94% 74.91% 74.91% 74.87%
3.27% 4.39% 4.57% 5.01% 4.81% 7.85% 6.74% 6.57% 6.42% 6.84% 5.08% 5.30%
0.58% 0.64% 0.74% 1.41% 1.57% 4.16% 4.86% 5.19% 5.62% 5.47% 7.13% 7.27%
13.30% 12.13% 11.84% 10.73% 10.76% 12.99% 13.40% 13.25% 13.03% 12.79% 12.89% 12.55%
No. of Shareholders 2,08,2671,98,7641,85,5311,56,1831,49,3961,43,9601,46,8401,41,9771,38,5001,35,6431,32,7481,27,969

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls